Impact of controlled-release tablet design on Quality of Life in Patients with drug degradation instability

Jun Yang; Y. Huang; F. Zhou

doi:10.5281/zenodo.22813168

Authors

Jun Yang Department of Pharmaceutical Sciences, Fraser Institute of Drug Delivery Research Author https://orcid.org/6421-6226-4034-4203
Y. Huang Department of Clinical Drug Delivery Research, Murray Institute for Advanced Drug Delivery Research Author https://orcid.org/2097-9555-4085-6858
F. Zhou Department of Pharmaceutical Sciences, Tiber Academy of Drug Delivery Research Author https://orcid.org/4571-4218-1059-2768

DOI:

https://doi.org/10.5281/zenodo.22813168

Keywords:

controlled-release tablet, drug stability, quality of life, medication adherence, formulation design

Abstract

Graphical abstract

Background: Controlled-release (CR) tablets prolong a drug's contact with hydrating excipient, and the same feature that flattens the plasma profile can raise cumulative exposure to conditions that drive chemical degradation.

Objective: We examine how the choice among hydrophilic matrix, osmotic pump and multiparticulate CR platforms affects degradation-related instability risk, and how the resulting regimen disruption affects patient quality of life and adherence.

Methods: We synthesized formulation-mechanism, forced-degradation, accelerated-stability, and adherence/quality-of-life literature into an illustrative comparative framework across three representative CR platforms.

Results: Hydrophilic matrices show the longest hydration exposure and hydrolytic-degradation emphasis, osmotic pumps compartmentalize water contact, and multiparticulates carry coating-defect variability; adherence and quality-of-life burden scale with departure from once-daily dosing.

Conclusions: CR platform selection carries direct patient-experience consequences, not only pharmaceutical-technology ones, and stability-driven reformulation warrants the same adherence support as any other unplanned regimen change.

References

Higuchi, T. (1963) Mechanism of sustained-action medication: theoretical analysis of rate of release of solid drugs dispersed in solid matrices. Journal of Pharmaceutical Sciences, 52(12): 1145-1149. DOI: 10.1002/jps.2600521210

Korsmeyer, R.W., Gurny, R., Doelker, E., Buri, P., Peppas, N.A. (1983) Mechanisms of solute release from porous hydrophilic polymers. International Journal of Pharmaceutics, 15(1): 25-35. DOI: 10.1016/0378-5173(83)90064-9

Ritger, P.L., Peppas, N.A. (1987) A simple equation for description of solute release I. Fickian and non-Fickian release from non-swellable devices. Journal of Controlled Release, 5(1): 23-36. DOI: 10.1016/0168-3659(87)90034-4

Peppas, N.A. (1985) Analysis of Fickian and non-Fickian drug release from polymers. Pharmaceutica Acta Helvetiae, 60(4): 110-111.

Siepmann, J., Peppas, N.A. (2001) Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Advanced Drug Delivery Reviews, 48(2-3): 139-157. DOI: 10.1016/S0169-409X(01)00112-0

Siepmann, J., Siepmann, F. (2008) Mathematical modeling of drug delivery. International Journal of Pharmaceutics, 364(2): 328-343. DOI: 10.1016/j.ijpharm.2008.09.004

Gao, P., Skoug, J.W., Nixon, P.R., Ju, T.R., Stemm, N.L., Sung, K.C. (2013) Swelling of hydroxypropyl methylcellulose matrix tablets: 1. Characterization of swelling using a novel optical imaging method. Journal of Pharmaceutical Sciences, 102(9): 3184-3192. DOI: 10.1002/jps.23623

Theeuwes, F. (1975) Elementary osmotic pump. Journal of Pharmaceutical Sciences, 64(12): 1987-1991. DOI: 10.1002/jps.2600641218

Verma, R.K., Krishna, D.M., Garg, S. (2002) Formulation aspects in the development of osmotically controlled oral drug delivery systems. Journal of Controlled Release, 79(1-3): 7-27. DOI: 10.1016/S0168-3659(01)00550-8

Waterman, K.C., Adami, R.C., Alsante, K.M., Hong, J., Landis, M.S., Lombardo, F., Roberts, C.J. (2002) Stabilization of pharmaceuticals to oxidative degradation. Pharmaceutical Development and Technology, 7(1): 1-32. DOI: 10.1081/PDT-120002237

Byrn, S.R., Xu, W., Newman, A.W. (2001) Chemical reactivity in solid-state pharmaceuticals: formulation implications. Advanced Drug Delivery Reviews, 48(1): 115-136. DOI: 10.1016/S0169-409X(01)00102-8

International Conference on Harmonisation (2003) ICH Harmonised Tripartite Guideline Q1A(R2): Stability Testing of New Drug Substances and Products. ICH, Geneva.

Blessy, M., Patel, R.D., Prajapati, P.N., Agrawal, Y.K. (2014) Development of forced degradation and stability indicating studies of drugs-a review. Journal of Pharmaceutical Analysis, 4(3): 159-165. DOI: 10.1016/j.jpha.2013.09.003

Singh, S., Bakshi, M. (2000) Guidance on conduct of stress tests to determine inherent stability of drugs. Pharmaceutical Technology, 24(4): 1-14.

Waterman, K.C., Carella, A.J., Gumkowski, M.J., Lukulay, P., MacDonald, B.C., Roy, M.C., Shamblin, S.L. (2007) Improved protocol and data analysis for accelerated shelf-life estimation of solid dosage forms. Pharmaceutical Research, 24(4): 780-790. DOI: 10.1007/s11095-006-9201-4

Claxton, A.J., Cramer, J., Pierce, C. (2001) A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics, 23(8): 1296-1310. DOI: 10.1016/S0149-2918(01)80109-0

Saini, S.D., Schoenfeld, P., Kaulback, K., Dubinsky, M.C. (2009) Effect of medication dosing frequency on adherence in chronic diseases. American Journal of Managed Care, 15(6): e22-e33.

Ingersoll, K.S., Cohen, J. (2008) The impact of medication regimen factors on adherence to chronic treatment: a review of literature. Journal of Behavioral Medicine, 31(3): 213-224. DOI: 10.1007/s10865-007-9147-y

Vrijens, B., De Geest, S., Hughes, D.A., Przemyslaw, K., Demonceau, J., Ruppar, T., Dobbels, F., Fargher, E., Morrison, V., Lewek, P., Matyjaszczyk, M., Mshelia, C., Clyne, W., Aronson, J.K., Urquhart, J. (2012) A new taxonomy for describing and defining adherence to medications. British Journal of Clinical Pharmacology, 73(5): 691-705. DOI: 10.1111/j.1365-2125.2012.04167.x

Ware, J.E., Sherbourne, C.D. (1992) The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care, 30(6): 473-483.

WHOQOL Group (1998) Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychological Medicine, 28(3): 551-558. DOI: 10.1017/S0033291798006667

Testa, M.A., Simonson, D.C. (1996) Assessment of quality-of-life outcomes. New England Journal of Medicine, 334(13): 835-840. DOI: 10.1056/NEJM199603283341306

Marinker, M., Shaw, J. (2003) Not to be taken as directed. BMJ, 326(7385): 348-349. DOI: 10.1136/bmj.326.7385.348

Costa, P., Sousa Lobo, J.M. (2001) Modeling and comparison of dissolution profiles. European Journal of Pharmaceutical Sciences, 13(2): 123-133. DOI: 10.1016/S0928-0987(01)00095-1

Colombo, P., Bettini, R., Santi, P., Peppas, N.A. (2000) Swellable matrices for controlled drug delivery: gel-layer behaviour, mechanisms and optimal performance. Pharmaceutical Science and Technology Today, 3(6): 198-204. DOI: 10.1016/S1461-5347(00)00269-8

Maderuelo, C., Zarzuelo, A., Lanao, J.M. (2011) Critical factors in the release of drugs from sustained release hydrophilic matrices. Journal of Controlled Release, 154(1): 2-19. DOI: 10.1016/j.jconrel.2011.04.002

Carstensen, J.T., Rhodes, C.T. (2000) Drug Stability: Principles and Practices, 3rd edition. Marcel Dekker, New York.

Osterberg, L., Blaschke, T. (2005) Adherence to medication. New England Journal of Medicine, 353(5): 487-497. DOI: 10.1056/NEJMra050100

Cramer, J.A. (1998) Enhancing patient compliance in the elderly: role of packaging aids and monitoring. Drugs & Aging, 12(1): 7-15. DOI: 10.2165/00002512-199812010-00002

Rowe, R.C., Sheskey, P.J., Quinn, M.E. (eds.) (2009) Handbook of Pharmaceutical Excipients, 6th edition. Pharmaceutical Press, London.